Navigation Links
Regado Biosciences' REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
Date:5/14/2008

in a prestigious, clinically oriented, peer-reviewed publication."

Results from Regado's 1c study were presented previously at the American Heart Association's 2007 Scientific Sessions.

About REG1 Anticoagulation System Clinical Program

In the Phase 1c clinical study, the researchers randomized 39 healthy volunteers to receive either three consecutive REG1 treatment cycles or placebo. Each REG1 cycle consisted of an intravenous (IV) bolus of RB006 dosed at 0.75 mg/kg, followed an hour later by a descending dose of RB007, ranging from a 2:1 to 0.125:1 antidote:drug ratio (1.5 mg/kg to 0.094 mg/kg of RB007). Clinical and coagulation assessments were measured for 14 days.

The Phase 1 program included two additional studies. A Phase 1a study enrolled 84 healthy volunteers, while a Phase 1b study enrolled 50 patients with stable coronary artery disease who were receiving aspirin with or without clopidogrel. The results showed an IV bolus injection of RB006 achieved, in both study populations, a prompt, consistent, and dose-dependent prolongation of activated partial thromboplastin time (aPTT). In addition, a 1 mg/kg dose of RB006 resulted in essentially complete Factor IXa inhibition. The studies also demonstrated an IV bolus injection of RB007 administered in a 2:1 antidote:drug ratio successfully reversed prolonged aPTT within a median of one minute, with no rebound increase up to seven days. Despite dual antiplatelet use in 19 subjects, there were no major bleeding or other serious adverse events observed in either study.

Based upon the combined results of the Company's Phase 1a, 1b, and 1c studies, Regado initiated REVERSAL-PCI, a multi-center, open-label, randomized Phase 2a clinical study of the REG1 anticoagulation system. The Phase 2a study is enrolling 26 patients undergoing elective percutaneous coronary intervention (PCI) to assess whether REG1 can replace standard heparin therapy during the performance of coronary balloon an
'/>"/>

SOURCE Regado Biosciences
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
2. Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference
3. YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR AEROLEF(TM) AT AMERICAN PAIN SOCIETY ANNUAL MEETING
4. Pressure BioSciences, Inc. to Discuss First Quarter 2008 Financial Results and Provide Business Update
5. Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors
6. Sangamo BioSciences Announces First Quarter Conference Call and Webcast
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
8. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
9. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
10. YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR TWO OF ITS ANTI-CANCER DRUGS AT AACR ANNUAL MEETING
11. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 Three Lawrence ... 2014 Hydrogen Production R&D Award for ... splitting water using sunlight. , Shared with collaborators ... the University of Nevada, Las Vegas (UNLV), the ... models of photoelectrochemical solar-hydrogen production and corrosion processes. ...
(Date:8/28/2014)... DIEGO, California, USA (PRWEB) August 28, 2014 ... the Department of Physics and Optical Science and Director ... the University of North Carolina at Charlotte, and co-founder ... been elected to serve as the 2015 Vice President ... , SPIE 2014 President Philip Stahl announced recent election ...
(Date:8/28/2014)... WEST LAFAYETTE, Ind. A new research ... "nanomechanical" properties of tiny structures undergoing stress ... insights to improve designs for microelectronics and ... spectroscopy, reveals information about how heating and ... their mechanical properties. Researchers have discussed the ...
(Date:8/28/2014)... 2014  Next month, executives from clinical trial marketing firm ... beginning with Patient-Centered Clinical Trials 2014 , to be ... , September 4-5. Patient recruitment experts Bonnie A. ... will share insights on the benefits of employing an ... – from media to mobile apps – can be used ...
Breaking Biology Technology:Livermore Team Awarded for Hydrogen Production Research 2Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3BBK Worldwide Leads Sessions at Key September Events 2
... Neogen Corporation,(Nasdaq: NEOG ) announced today that ... which ended Nov. 30, increased 34% from the previous ... income in the,quarter rose to $0.22 per share, compared ... of $3,254,000 set another quarterly,record for the 25-year-old company., ...
... 3 /PRNewswire/-- Intercept Pharmaceuticals, Inc., a,clinical-stage biopharmaceutical ... fibrotic and metabolic diseases, today announced the,appointment ... created position of,Chief Scientific Officer. Dr. Adorini ... research and development, recently serving as Chief ...
... Chimerix, Inc., a,biotechnology company developing orally available ... FRCA, FFPM has joined the,company as Chief Medical ... served as the Chief Medical,Officer and Chief Operating ... was responsible for the design of clinical drug,development ...
Cached Biology Technology:Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 2Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 3Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 4Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 5Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer 2Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer 2
(Date:8/29/2014)... German . ... nitrogen cycle on Earth and in biological wastewater treatment ... depend on nitrite as their source of energy. An ... microbiologist at the University of Vienna, has now shown ... source of energy. The oxidation of hydrogen with oxygen ...
(Date:8/29/2014)... as the prolific bloomer Emiliania huxleyi , can ... The finding contradicts the common view that E. ... scarce supplies of thiamine in the ocean to survive. ... the ocean," says CIFAR Senior Fellow Alexandra Worden ... with CIFAR fellows John Archibald (Dalhousie University), ...
(Date:8/29/2014)... them, fold them: modern materials that are light, flexible ... artificial skin or electronic paper. , Making such concepts ... a new way of working with copper nanowires and ... , Previous success in the field of ultra-lightweight "aerogel ... gold and silver nanowires. , By turning instead ...
Breaking Biology News(10 mins):Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3Copper shines as flexible conductor 2
... November 15, 2013 Millions of families in the ... to insufficient money or other resources. To combat food ... upon the Supplemental Nutrition Assistance Program (SNAP), the largest ... In the past, SNAP has been shown to reduce ...
... , Nov. 14, 2013  Shareholder rights law firm Robbins Arroyo ... (NASDAQ: VICL ) has filed a federal securities ... the Southern District of California.  The complaint alleges that the ... Exchange Act of 1934 between February, 8, 2012 and August ...
... (Nov. 14, 2013) -- A low-cost device that Rice ... more easily will be rolled out to teaching hospitals ... from pharmaceutical giant GlaxoSmithKline (GSK) and London-based charity Save ... CPAP," earned the top prize in GSK and Save ...
Cached Biology News:Enrollment in SNAP does not substantially improve food security or dietary quality 2Attention Vical Incorporated Investors: Vical Misled Investors According to a Newly Filed Class Action 2Prize will expand use of life-saving neonatal device in Africa 2Prize will expand use of life-saving neonatal device in Africa 3
Anti-gamma Glutamyl Transferase (gammaGT) Host: mouse monoclonal Species Reactivity: human Applications: WB, IP, FC Storage: 4C...
Anti-DDDDK-Tag (Enterokinase Cleavage Site), Agarose Conjugate Research Focus: tag Storage: 4C Shipping Temperature: 4C...
Anti-ACTH Immunogen: Porcine ACTH conjugated to BSA. Available Date: 38566...
Rabbit polyclonal to SERHL ( Abpromise for all tested applications). entrezGeneID: 94009 SwissProtID: Q9H4I8...
Biology Products: